Urology Medical News about prostate cancer; leuprorelin acetate

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
Clinical Interventions in Aging, 06/08/09

Sethi R et al. - Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-month depot leuprorelin formulations are well established and widely used to this end. Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment option for these patients. This review will highlight the role of GnRH agonists in the treatment of prostate cancer with a focus on the clinical efficacy, pharmacology, and patient-focused outcomes of the newer 6-month 45 mg depot leuprorelin formulation in comparison to available shorter-acting products.

<< Previous
Intravenous versus oral iron supplementation for correction of...

Next >>
Immunogenicity of 56°C and UVC-treated prostate cancer is...